• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Rigid gas permeable contact lens deposition measured via radiolabeled proteins


The Biosciences group of the Centre for Ocular Research and Education (CORE) determined protein deposits on rigid gas permeable contact lens via radioactive counts by using a radiolabeled lysozyme in an artificial tear solution.

rigid gas permeable contact lens with case and solution

Image courtesy of Adobe Stock/Valeri Luzina

At the 2023 Global Specialty Lens Symposium, Centre for Ocular Research and Education’s (CORE) Biosciences group presented a scientific post on an investigation of protein deposits rigid gas permeable (RGP) contact lens deposition via a novel method: Incorporating radiolabeled lysozyme into an artificial tear solution, which allows researchers to determine on-lens protein through radioactive counts.1

Investigators soaked 7 common RGP lens materials in the radioactive artificial tear solution for 16 hours, then exposed to a 3% one-step hydrogen peroxide (OSP) care solution for 8 hours to evaluate cleaning ability.

The deposits were minimal without use of a cleaning solution. The deposits ranged from 1.2 ± 0.2 μg to 3.2 ± 0.7 μg per RGP lens. After 30 alternating incubating and cleaning cycles with OSP solution, the amount of radioactive lysozyme on the RGP lenses reduced significantly when compared to using phosphate buffered saline. With the OSP solution, the remaining lysozyme on cleaned lenses ranged from 1.3 ± 0.1 μg to 2.5 ± 0.1 μg per lens.

“Renewed interest in RGP lenses around the world, sparked by the rise in their use for myopia management, has subsequently increased the desire for more advanced research. CORE has built a reputation for discovering new ways to precisely assess ophthalmic devices and pharmaceuticals, and this radiolabeling technique has strong potential for other applications,” Alex Hui, OD, PhD, FAAO, head of Biosciences at CORE, said in a press release.

The unique approach was previously used to study soft contact lens deposition in the past, but it was the first time radiolabeled lysozyme was used to investigate protein deposits on RGP contact lenses.

The investigation, conducted by the CORE Biosciences group, was initially presented as a scientific poster at the 2023 Global Specialty Lens Symposium: "The impact of RGP care solutions on ISO measured lens parameters and the protein deposition on RGP lenses when managed with a hydrogen peroxide care solution," Hui, et al. The study was supported by funding from CooperVision.

CORE’s Biosciences group delves into important research regarding ocular surface and biomaterials, especially contact lenses. In 2022, CORE broadened its specialty contact lens investigations to examine design optimization for orthokeratology, scleral lens physiological performance, and the effect of scleral lenses on ocular surface disease and dry eye.

CORE Biosciences group uses radiolabeled proteins to study RGP contact lens deposition. Press release. Centre for Ocular Research and Education. February 13, 2023. Accessed February 13, 2023.
Related Videos
Jade Coats, OD, outlines two poster presentations she gave on a novel lipid-containing eye drop at the AOA Optometry's Meeting
William Reindel, OD
Andrew Pucker, OD, PhD
Marjorie Rah, OD, PhD, FAAO
Amy Butler of Bausch + Lomb details the company's recycling programs and initiatives for contact lenses and other eye care products
Jessica Steen, OD, FAAO, discusses systemic medication and ocular adverse effects at Vision Expo East 2024
At Vision Expo East 2024, Srinivas Kondapalli, MD, demonstrates how to use Rinsada to address ocular surface disease.
© 2024 MJH Life Sciences

All rights reserved.